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While mesenchymal stem cells (MSCs)-based therapy appears to be promising, there 
are concerns regarding possible side effects related to the unwanted suppression of 
antimicrobial immunity leading to an increased risk of infection. Conversely, recent data 
show that MSCs exert strong antimicrobial effects through indirect and direct mecha-
nisms, partially mediated by the secretion of antimicrobial peptides and proteins (AMPs). 
In fact, MSCs have been reported to increase bacterial clearance in preclinical models of 
sepsis, acute respiratory distress syndrome, and cystic fibrosis-related infections. This 
article reviews the current evidence regarding the direct antimicrobial effector function 
of MSCs, focusing mainly on the role of MSCs-derived AMPs. The strategies that might 
modulate the expression and secretion of these AMPs, leading to enhanced antimicro-
bial effect, are highlighted. Furthermore, studies evaluating the presence of AMPs in 
the cargo of extracellular vesicles (EVs) are underlined as perspective opportunities to 
develop new drug delivery tools. The antimicrobial potential of MSCs-derived EVs can 
also be heightened through cell conditioning and/or drug loading. Finally, improving the 
pharmacokinetics and delivery, in addition to deciphering the multi-target drug status of 
AMPs, should synergistically lead to key advances against infections caused by drug- 
resistant strains.
Keywords: mesenchymal stromal cells, mesenchymal stem cells, antimicrobial effect, antibacterial 
property, AMPs
iNTRODUCTiON
Human mesenchymal stem or stromal cells (MSCs) are self-renewing multipotent cells with great 
potential for regenerative medicine and tissue engineering. MSCs are located within the stroma 
of the bone marrow (BMSCs) and other organs, including adipose tissue (AT-MSCs), dental pulp 
(DP-MSCs), postnatal tissues, such as umbilical cord (UC-MSCs) and placenta (PL-MSCs), or 
menstrual fluid (MenSCs), with each MSCs-population displaying individual differentiation poten-
tial and phenotype (1–7). According to the Mesenchymal and Tissue Stem Cell Committee of the 
International Society for Cellular Therapy (ISCT, www.celltherapysociety.org/), the minimal criteria 
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for defining human MSCs are (a) adherence to plastic surface; (b) 
specific surface antigen expression (Positive expression of CD105, 
CD73, and CD90, and lack expression of CD45, CD34, CD14 or 
CD11b, CD79a or CD19, and HLA-DR); and (c) multipotent dif-
ferentiation potential to osteoblast, adipocytes, and chondroblasts 
using standard in  vitro tissue culture-differentiating conditions 
(8). Their versatility, homing preference for injured tissue, their 
immune privileged status, and the lower risk of tumorigenesis 
render them an interesting instrument in cell-based therapy (7). 
Due to their differentiation plasticity, immunomodulatory prop-
erties, angiogenic modulation, and paracrine support (9–13), 
MSCs have been investigated in a wide spectrum of disease 
indications, which is evidenced in the ~500 trials enrolled in the 
ClinicalTrials.gov database of the NIH (http://www.clinicaltrials.
gov/, queried in December 2016).
Despite the demonstrated biologic effect and regenerative 
properties of MSCs in  vitro and in  vivo, the exact knowledge 
about their mechanism of action is still unknown. However, it 
is now widely accepted that MSCs exert their effect by paracrine 
stimulations through the release of small molecules as growth 
factors, cytokines, and chemokines (14, 15). Although initial 
clinical results of MSCs-based therapy showed promising out-
comes, there are significant concerns that application of MSCs 
may inadvertently suppress antimicrobial immunity with an 
increased risk of infection (16). On the other hand, current data 
suggest that MSCs exert strong antimicrobial effects through 
indirect and direct mechanisms (16–26). Indirectly, across their 
role in the host immune response against pathogens, especially 
in the dynamic coordination of the pro- and anti-inflammatory 
elements of the immune system (22, 27–29) or increasing the 
activity of phagocytes (18, 21, 25, 30, 31); and directly, by the 
secretion of antimicrobial peptides and proteins (AMPs) (19, 
20, 23, 24, 26), and also by the expression of molecules such as 
indoleamine 2,3-dioxygenase (IDO) (16) and interleukin (IL)-17 
(32). In fact, MSCs have been reportedly responsible of the bacte-
rial clearance in preclinical models of sepsis (17–20, 22, 25), acute 
respiratory distress syndrome (ARDS) (21, 26), and cystic fibrosis 
infection (23).
AMPs or host-defense peptides and proteins are an abundant 
and diverse group of endogenous molecules that are produced as 
a first line of defense by all multicellular organisms which have a 
broad spectrum of antimicrobial and immunomodulatory activi-
ties (33). These molecules have selective activity against a wide 
range of organisms including bacteria, yeasts, fungi, viruses, and 
even cancer cells (34). So far, MSCs have been found to consti-
tutively express four AMPs: cathelicidin LL-37 (19, 23), human 
β-defensin-2 (hBD-2) (24), hepcidin (20), and lipocalin-2 (Lcn2) 
(26), which can be further modulated during infection and 
inflammation. In fact, it has been demonstrated that, in MSCs, 
a bacterial preconditioning induces an upregulation of LL-37, 
hBD-2, and hepcidin (19, 20, 24), while their preconditioning 
with inflammatory stimuli evoke increasing levels of LL-37 and 
Lcn2 (23, 26). In different preclinical models, MSCs-derived 
AMPs have demonstrated to be part of the bacterial clearance 
effect observed with MSCs treatment, revealing that MSCs can 
directly enhance the innate immune response to bacterial infec-
tion (19, 20, 23, 24, 26).
In this review, we summarize the current evidence regarding 
the direct antimicrobial effector function of MSCs, focusing 
mainly in the role of the MSCs-derived AMPs. The different strat-
egies that could modulate the expression and secretion of these 
AMPs and enhance their antimicrobial effect are emphasized. We 
also underline the presence of AMPs in the cargo of extracellular 
vesicles (EVs) present in body fluids and secreted by different 
type of cells including activated MSCs.
ANTiMiCROBiAL PePTiDeS
Antimicrobial peptides are evolutionary conserved gene-encoded 
small effector molecules (10-150aa) found in organisms from 
procaryotes to humans (34, 35). Some of these antimicrobial pep-
tides are present constitutively, while others may be induced in 
response to infection or inflammatory conditions. AMPs display 
different mechanisms of action (MoA) leading to the elimination 
of microorganisms, some of which are also dependent on external 
factors, such as pH, peptide abundance, and salt concentration 
(33, 36).
Human AMPs interact with different molecular targets either 
on the cell surface or within the cells. AMPs-mediated cell killing 
occurs by disrupting membrane integrity, by inhibiting protein, 
DNA or RNA synthesis, and by interacting with certain intracel-
lular targets (33). In general, AMPs are only effective against one 
class of pathogen (e.g., bacteria or fungi); however, some AMPs 
display MoA against several types of microorganisms (37). 
Importantly, in some specific cases, AMPs can be active against 
pathogens that are resistant to conventional antibiotics (ABs) as 
multidrug-resistant bacteria. These advantageous features make 
AMPs good candidates for drug development, although their 
clinical and commercial development still needs to overcome 
challenges, such as route of administration, potential toxicity, 
stability, and high cost of peptide production (38).
AMPs are also called “host defense peptides,” a terminol-
ogy that emphasizes their immunomodulatory functions (39). 
These functions are diverse, specific to the type of AMPs, and 
include different cytokines and growth factor-like effects that 
are relevant to both innate and adaptive immune responses (34). 
Hence, AMPs can also help to resolve inflammation or infections 
through indirect effects, which act in synergy with the direct 
antimicrobial activity.
To date, more than 2,700 AMPs of different sources have been 
registered in the Antimicrobial Peptide Database (APD, http://
aps.unmc.edu/AP/main.php; last updated on sixth January 2017) 
including 115 that are human host defense peptides. In Table 1, 
we have summarized some representative human AMPs and 
their characteristics in terms of source, activity, 3D structure, 
and length.
Besides their antimicrobial activities, AMPs also show indirect 
biological effects that may help to eradicate infection (66). In this 
context, it has been described that AMPs secreted by epithelial 
cells present a battery of biological features including chemokine 
and anti-endotoxin activities as well as protease inhibition, bac-
terial opsonization, and angiogenic properties (66). Specifically, 
cathelicidins are chemotactic for monocytes, neutrophils, and 
lymphocytes (67) and it has been demonstrated that LL-37 
TABLe 1 | Human selected antimicrobial peptides.
Name Source Activity 3D 
structurea 
(35)
Length 
(aa)
Reference
α β αβ
Cathelicidin LL-37 Neutrophils, skin monocytes, lymphocytes, MCS, sweat, airway surface liquid, 
saliva
G, V, F, P, C √ 37 (40)
Dermcidin Skin, sweat G, F √ 47 (41)
Granulysin Cytolitic T and NK cells G, F, P, C √ 74 (42)
Histatin 5 Saliva V, F √ 24 (43)
Lactoferricin Human milk, tears, saliva, bronchial mucus, and seminal plasma G, V, F, P √ 49 (44)
Lysozyme Saliva, tears, intestine G, F √ 130 (45)
Psoriasin/S100A7 Skin, salivary gland, breast G− √ 101 (46)
α-Defensin HNP-1 Neutrophils, bone marrow G, V, F, P, C √ 30 (47)
α-Defensin HNP-2 Neutrophils, bone marrow G, V, F, C √ 29 (47)
α-Defensin HNP-3 Neutrophils, bone marrow G, V, F, C √ 30 (47)
α-Defensin HNP-4 Neutrophils G, V, F √ 33 (48)
α-Defensin HD-5 Paneth cells, intestine, female reproductive system G, V, F √ 32 (49)
α-Defensin HD-6 Paneth cells, intestine G, V, F √ 32 (50)
Hepcidin 20 Plasma, urine, liver G, F √ 20 (51)
Hepcidin 25 (LEAP-1) Plasma, urine/liver heart, kidney, adipose tissue, pancreas and hematopoietic cells, 
MSCs, myeloid cells (monocytes, macrophages, neutrophils)
G, F √ 25 (51)
Secretory leukoprotease 
inhibitor (SLPI)
Tears, saliva, airway, gastrointestines, genital tracts G, V, F √ 102 (52)
RNase 5 angiogenin Liver, skin, intestine G+, F √ 125 (53)
Chemokine CCL1 T cells G √ 73 (54)
Chemokine CCL8 Fibroblasts, endothelial cells G− √ 75 (54)
Chemokine CCL13 Epithelial cells, mononuclear cells G- √ 75 (54)
Chemokine CCL20 Skin, B cells, myeloid dendritic cell, memory T cell G, F, P √ 69 (54, 55)
Chemokine CCL27 Memory T cell F √ 56 (56)
Chemokine CXCL1 Macrophages, neutrophils, epithelial cells G √ 73 (54)
Chemokine CXCL10 Monocytes, endothelial cells, fibroblasts G, F, P √ 77 (57)
β-Defensin hBD-1 Kidney, skin, salivary glands G, F, C √ 36 (58)
β-Defensin hBD-2 Skin, lung, epithelia, uterus, salivary glands G, V, F √ 41 (58)
β-Defensin hBD-3 Skin, salivary glands G, V, F √ 45 (58)
Neutrophil gelatinase-
associated lipocalin (NGAL, 
Lcn2)
Bone marrow, uterus, prostate, salivary gland, stomach, appendix, colon, 
trachea, lung, small intestine, pancreas, kidney and prostate. MSCs, neutrophils, 
macrophages, and dendritic cells
G √ 178 (59–63)
RegIIIα Intestine G+ √ 149 (64)
RNase 7 Urinary tract, respiratory tract, skin G, F √ 128 (65)
aData from the APD (http://aps.unmc.edu/AP/database/query_input.php). Antimicrobial activities are annotated as G, bacteria; G+, Gram-positive bacteria only; G−, Gram-negative 
bacteria only; F, fungi; P, parasites; V, viruses; C, cancer cells.
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binds and neutralizes lipopolisacharide (LPS), protecting against 
endotoxic shock in a mouse model of septicemia (68). Likewise, 
β-defensins are chemotactic for macrophages, neutrophils, and 
mast cells, possibly by binding to CCR6 (69). As for hepcidin (70, 
71) and Lcn2 (34, 72) they are involved in pathways regulating the 
availability of iron, a vital element for bacterial growth.
Recently, MSCs have also been described to possess antimi-
crobial activity, which would be given by antimicrobial peptides 
or proteins of members of the cathelicidins (19, 23), defensins 
(24), hepcidin (20), or lipocalin families (26).
Cathelicidins, defensins, and hepcidin are synthesized as 
pre–pro peptides that are cleaved to release mature AMPs that 
interact with negatively charged bacterial membrane surface (73). 
Lipocalins (Lcns) are characterized by their ability to bind small 
hydrophobic molecules, their binding to specific cell-surface 
receptors, and their formation of macromolecular complexes (74).
Cathelicidins
To date, only one cathelicidin gene (CAMP) has been described in 
mice and human, inducing a protein named CRAMP and LL-37, 
respectively (75). LL-37 exhibits a broad spectrum of antimicrobial 
activity, several immunomodulatory effects, anticancer activities, 
and also chemotactic and pro-angiogenic properties (35, 40). It 
has been detected in several types of cells, tissues, and fluids, and 
along with other AMPs, such as β-defensins, plays a central role 
in mucosal defense (76). An increased or decreased expression of 
LL-37 has been identified in several diseases, observing elevated 
levels in inflammatory pathologies like systemic lupus erythema-
tosus and pulmonary diseases (77–79). In contrast, low production 
of LL-37 is associated with asthma and skin disorders (80–82).
The expression of LL-37 is driven by several stimuli such as 
inflammatory mediators and microbial structures, and varies 
depending on cell type (83) (Table 2). Vitamin D3 appears to be 
TABLe 2 | Factors that can modulate LL-37, hBD-2, hepcidin, and Lcn2 expression.
LL-37 hBD-2 Hepcidin Lcn2
Factor upregulation Reference Factor upregulation Reference Factor upregulation Reference Factor upregulation Reference
IL-17A (in synergy with vitamin D3) (84) LPS (85) IL-6, IL-1α, IL-22, oncostatin M (86, 87) Anemia (88)
TNFα, IFNγ (89, 90) IL-1, TNFα (91) Activin B (92) LPS (62)
Injury, wounding, UVB irradiation (89, 93) TLR-2 (94, 95) Liver metabolic activities (96) IL-1α and β, IL-4, IL-17, IL-22, IL-9, 
TNFα
(97–104)
Sodium butyrate, phenyl butyrate (105–107) IL-17 (76) Oxygenases (96) IGF-1, TGFα (108)
TLR agonists, lithocholic acid, 
vitamin D receptor agonists 
(89, 109–112) AP-1, MEF (94, 113) Small molecule activators of Stat/Smad pathways 
(genistein)
(114) Serum, growth factors, phorbol esters, 
Glucocorticoids (dexamethasone)
(115, 116)
ER stress (93) Neutrophil elastase (117) BMP6 (118) 3-cis retinoic acid (isotretinoin); 4-HPR (119, 120)
Short-chain fatty acids, Zn2+, lactose (121–123) Calcium (124) TMPRSS6 siRNA or ASOs (125) MK886, nordihydroguaiaretic acid (126, 127)
BCG (128) UV light (89) HFE, TfR2 (96) COX-2 inhibitors, celecoxib-derived 
PDK1 inhibitors 
(126)
Factor downregulation Reference Factor 
downregulation
Reference Factor downregulation Reference Factor downregulation Reference
Bacterial exotoxins, Shigella, 
Neisseria infection
(107, 129–131) Glucocorticoids 
(dexamethasone)
(76, 124) Oxidative stress (ROS); hypoxia; heparin; anti-
inflammatories (anti-IL-6/IL-6R (siltuximab)/
(tocilizumab), anti-TNFα, AG490)
(96, 132–136) l-Glutamine, N-acetylcysteine (137, 138)
IL-6, IFNγ, calcipotriol (89, 139) Calcium quelator (124) Matriptase2, s-HJV-Fc, GDF15, erythropoiesis-
stimulating agents
(96, 132, 
140)
Paricalcitol (141)
Psychological stress; transmigration 
across activated endothelium
(142, 143) Inhibitors of NF-κB 
and AP-1
(124) Small molecule inhibitors of the BMPR type I kinase 
(LDN-193189); anti-BMP6 antibody; HJV ASOs, 
hepcidin ASOs or siRNA, TfR2 siRNA; PpYLKTK 
(disruptor of STAT3 dimerization)
(118, 140, 
183–187)
EGF, miR-138 (144, 145)
IL-17A, interleukin-17; TNF, tumor necrosis alpha; IFN, interferon; UV, ultraviolet light; IL-6, interleukin 6; LPS, lipopolysaccharide; IL-1, interleukin 1; IL-22, interleukin 22; TLR, toll-like receptor; BCG, Mycobacterium bovis bacillus 
Calmette–Guérin; AP-1, activator protein 1; MEF, myeloid elf-1-like factor; NF-κB, nuclear factor-κB; BMP6, bone morphogenetic protein 6; TMPRSS6, transmembrane protease serine 6; siRNA, small interfering RNA; HFE, human 
hemochromatosis protein; TfR2, transferrin receptor 2; s-HJV-Fc, soluble form of hemojuvelin; GDF15, growth differentiation factor 15; BMPR, bone morphogenetic protein receptor; STAT3, signal transducer and activator of 
transcription 3; ASOs, antisense oligonucleotides; HJV, hemojuvelin; EGF, epidermal growth factor; COX-2, cyclooxygenase-2; PDK1, phosphoinositide-dependent kinase 1; 4-HPR; N-(4-hydroxyphenyl)retinamide; ER, endoplasmic 
reticulum; miR-138, microRNA-138; IGF-1, insulin like growth factor-1; TGFα, transforming growth factor alpha.
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the major regulator of LL-37 expression in humans as the CAMP 
gene encoding LL-37 contains three VDREs (Vitamin D response 
element) on its promoter. Upregulating the expression of natural 
LL-37 or developing synthetic mimics might represent a potent 
new therapeutic option that needs to be carefully evaluated.
Defensins
The defensin family of AMPs can be classified as α-defensins, 
β-defensins, or θ-defensins depending on their cellular origin, 
gene structure, and connectivity of the cysteine residues in their 
sequence (75). Defensins play important roles in innate and 
adaptive immunity against microbial and viral infections and also 
participate in wound repair, cytokines and chemokine expres-
sion, production of histamine, and enhancement of antibody 
responses (58).
β-Defensins, hBD-1, hBD-2, and hBD-3 are the mainly 
functional peptides in humans (35) expressed by many epithelial 
cells, granulocytes, and MSCs (24). Except for hBD-1, their 
expression is inducible (75), hBD-2 and hBD-3 are induced by 
pro-inflammatory stimuli or microorganisms (91, 146). hBD-1 
and 2 are microbicidal predominantly against Gram-negative 
bacteria, while hBD-3 is a broad-spectrum antimicrobial pep-
tide. Given their significant antimicrobial and antiviral activity, 
modulating endogenous defensin production through the use of 
specific regulatory stimuli makes defensins promising candidates 
for therapy (Table 2). Direct administration to sites such as the 
skin or cervico-vaginal mucosa for treatment of wounds or infec-
tion is of interest, particularly in conditions where antimicrobial 
peptide generation is reduced (76).
Hepcidin
Hepcidin is a natural human host defense peptide, originally 
found in urine and plasma (147, 148) which is produced mainly 
by hepatocytes but also by other cells including MSCs and 
myeloid leukocytes (71).
Hepcidin is known to act as an iron regulatory hormone, as 
well as it exerts a broad spectrum of antimicrobial activity against 
fungal species and clinical relevant bacteria such as Escherichia 
coli, S. epidermidis, S. aureus, and group B streptococci; however, 
the role as an antimicrobial peptide remains to be further unrave-
led for most type of infections (51, 147). Both peptides forms of 
hepcidin (hep-20 and hep-25) exhibit antimicrobial properties 
(147); however, hep-20 is not involved in the regulation of iron 
use (149).
The expression of hepatocyte hepcidin is regulated by iron 
status through the BMP-SMAD pathway and by inflammation, 
where the binding of inflammatory cytokines like IL-6 triggers 
the JAK–signal transducer and activator of transcription 3 
(STAT3) signaling pathway (150, 151). An hepcidin-mediated 
hypoferremia could functions as a host defense mechanism that 
evolved to restrict iron availability and slow the pathogen growth 
(70, 71). The enhancement of bactericidal activity at low pH 
renders these peptides interesting for the development of drugs 
specifically designed, for example, for bacterial and/or fungal 
infections occurring in body areas with acidic pH (51, 152). Thus, 
modulation of the hepcidin pathway (Table  2) has become an 
interesting target for new therapeutic strategies (140).
Lipocalins
Lipocalins are a family of small soluble proteins, which are often 
secreted (88). Lcns functions as transporters binding small 
organic molecules that have been associated with many biological 
processes: the immune response, cell growth, proliferation and 
metabolism, synthesis of prostaglandins, and iron transportation 
(153). Lcn2 appears to have an important role in innate anti-
microbial defense mechanism (154) and in contrast with other 
AMPs, it exerts an indirect function against pathogens.
Originally, Lcn2 was identified as a component of neutro-
phil granules; however, it was later shown to be also expressed 
in various cells such as macrophages, adipocytes, MSCs, and 
epithelial cells in response to inflammatory conditions (26, 115, 
153, 155) (Table 2). The antimicrobial role is given by its ability 
to sequesters bacterial iron chelators, called siderophores, that 
consequently prevent the iron transfer to bacteria and arrested 
their growth (bacteriostatic effect) (34, 72). This function was 
demonstrated using mice genetically lacking Lcn2 that showed a 
marked increase in mortality in an E. coli-induced sepsis model 
(155, 156). Other studies revealed that Lcn2 also binds other 
types of siderophores, such as bacillibactin (B. anthracis) (157) 
and carboxy-mycobactin (mycobacteria) (158). Lcn2 is one of the 
most commonly studied novel biomarkers (159) and has emerged 
as a promising biomarker for different pulmonary diseases (97), 
kidney injury (160–163), liver failure (164), and tumorigenesis 
(144). Thus, the clinical relevance of Lcns is rapidly increasing 
even though the exact mechanisms behind their functions remain 
to be elucidated.
ANTiMiCROBiAL eFFeCTOR FUNCTiON 
OF MSCs
In Vitro Studies
Most of the data about the antimicrobial properties of MSCs have 
been obtained from in vitro studies with bacteria, although little 
data exist about the effect of MSCs on viral, fungal, and parasite 
pathogens. For both unstimulated and stimulated MSCs, a direct 
antimicrobial effect has been described (Table 3).
The antimicrobial efficacy of MSCs mediated by AMPs has 
been described for different sources of stromal cells, although 
different MoA and antibacterial range have been reported for 
them. Probably, these variations in the antimicrobial spectrum of 
MSCs might be a specific response of MSCs to produce the most 
effective AMPs against a specific type of pathogen challenge. A 
summary of the types of AMPs detected and not detected in the 
different sources of MSCs are shown in Table  4. Likewise, the 
data available to date suggest notable species-specific difference 
between murine and human MSCs with regard to the MoA of the 
antimicrobial effector function of MSCs (16).
BMSCs are the most studied source regarding the intrinsic 
antimicrobial ability of MSCs. In humans, the antimicrobial effect 
of BMSCs is mediated by LL-37 (19, 23) and hepcidin (20).
These AMPs have been detected in both unstimulated and 
stimulated-BMSC cultures. Respect to LL-37, BMSCs as well 
as their conditioned medium has demonstrated the property to 
inhibit the bacterial growth of E. coli, Pseudomonas aeruginosa, 
TABLe 4 | Summary of AMPs types described in MSCs according to their source of origin.
Type of MSCs Types of AMPs
LL-37 Hepcidin β-Defensins SP-D Lipocalin-2 Reference
hBD-1 hBD-2 hBD-3
BMSCs √ √ x √/x x x x (19, 20, 23)
muBMSCs – – – – – – √ (26)
AT-MSCs – – – – – – – (23)
MenSCs x √ x x x – – (20)
UC-MSCs x – – √ – – x (24)
MSCs, human mesenchymal stem cells; BMSCs, bone marrow MSCs; muBMSCs, murine BMSCs; MenSCs, menstrual MSCs; AT-MSCs, adipose tissue MSCs; UC-MSCs, 
umbilical blood cord MSCs; hBD, human β-defensin; SP-D, surfactant protein-D; √, detected; x, not detected; –, not determined.
TABLe 3 | Summary of direct antimicrobial effects of MSCs on bacterial, fungal, parasite, and viral pathogens.
MSCs stimuli Activity Mechanism of action Reference
Bacteria-stimulated BMSCs Growth inhibition of Gram-negative (Escherichia coli, 
Pseudomonas aeruginosa) and Gram-positive (S. aureus)
↑ LL-37 (19)
Unstimulated and bacteria-stimulated MenSCs 
and BMSCs
Growth inhibition of a mix of bacteria ↑ Hepcidin (20)
Unstimulated and stimulated BMSCs and 
AT-MSCs with inflammatory stimuli
Growth inhibition of Gram-negative (P. aeruginosa) and Gram-
positive (S. aureus; S. pneumoniae)
↑ LL-37 (23)
Bacteria-stimulated UC-MSCs Growth inhibition of Gram-negative (E. coli) ↑ hBD-2 (24)
Stimulated muBMSCs with inflammatory stimuli Inhibition of bacteria growth ↑ Lipocalin-2, ↑ Phagocytic activity (26)
IFNγ-stimulated BMSCs Growth inhibition of Gram positive (S. aureus; S. epidermidis; 
E. faecium; Group B streptococci) and parasite (Toxoplasma 
gondii), and reduction in virus replication (CMV and HSV-1)
↑ IDO (16)
muBMSCs producing IL-17 Growth inhibition of Candida albicans ↑ IL-17 (32)
MSCs, human mesenchymal stem cells; BMSCs, bone marrow MSCs; muBMSCs, murine BMSCs; MenSCs, menstrual MSCs; AT-MSCs, adipose tissue MSCs; UC-MSCs, umbilical 
cord MSCs; IFNγ, interferon gamma; IL, interleukin; hBD-2, human β-defensin-2; IDO, indoleamine 2,3-dioxygenase; CMV, cytomegalovirus; HSV-1, herpes simplex virus type-1.
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S. aureus, and S. pneumonia (19, 23). In the study performed by 
Krasnodembskaya et  al. (19), the authors showed that BMSCs 
are able to inhibit bacterial growth directly, also by means of 
conditioned culture medium, but only when BMSCs were previ-
ously challenged with bacteria. They also showed that BMSCs 
produce and secrete inducible quantities of LL-37, responsible 
for the inhibition of bacterial growth of E. coli and P. aeruginosa 
in vitro. In contrast, hBD-2-3, Lcn2, and surfactant protein D (SP-
D) were negative in BMSCs or expressed very low protein levels, 
which were insufficient to elicit an antibacterial effect. Likewise, 
these cells exhibit direct antimicrobial activity against S. aureus, 
through a contact-independent mechanism and mediated in part 
by the release of LL-37. Recently, Sutton et al. (23). demonstrated 
that BMSCs constitutively secrete LL-37, which exert a potent 
antimicrobial effect in vitro against P. aeruginosa, S. aureus, and 
S. pneumonia, controlling the rate of bacterial growth and transi-
tion into colony forming units. These data suggest that BMSCs 
supernatants can be useful as an adjunct treatment to conven-
tional ABs. Interestingly, the levels of LL-37 were enhanced 
after the preconditioning with inflammatory stimulus, as IFNγ, 
IL-1β, or IL-12. However, in line with previous report (19, 20), 
the levels of hBD-2-3 were not detected in unstimulated nor 
stimulated BMSCs (23). Furthermore, the levels of LL-37 were 
detected in BMSCs only when the cell growth was performed 
under FBS (fetal bovine serum) condition, since the serum-free 
or platelet lysate conditions reduce the antimicrobial efficacy of 
BMSCs and their production of LL-37 (23). Conversely with the 
aforementioned data, in which expression of the antimicrobial 
peptide LL-37 was detected constitutively in BMSCs or following 
stimulation with E. coli or inflammatory stimulus, data from our 
research group did not show any basal or induced expression 
of LL-37 under both bacterial mixture and LPS stimulations in 
BMSCs. However, we detected in bacteria-stimulated BMSCs the 
expression of hepcidin, which was involved in the antimicrobial 
effect of MSCs both direct and in conditioned medium (20).
The antimicrobial properties of MSCs is not only limited 
to AMPs activity. In fact, upon stimulation with inflamma-
tory cytokines, BMSCs through a substantial increase in IDO 
expression, exhibit a cell autonomous, broad-spectrum antimi-
crobial effector function directed against clinically relevant bac-
teria (S. aureus; S. epidermidis; E. faecium; Group B streptococci), 
 protozoal parasites (Toxoplasma gondii), and viruses (CMV 
and HSV-1) (16). Also, it has been reported that IL-17-positive 
murine(mu)BMSCs exert a potent antifungal activity with respect 
to IL-17-negative or bulk muBMSCs. The growth inhibition of 
Candida albicans is mediated by IL-17 in a dose-dependent man-
ner, while anti-IL-17 antibodies partially reduce anti-C. albicans 
effect of muBMSCs (32).
Potent antimicrobial effects of muBMSCs have also been 
described on E. coli and C. albicans but with a different 
MoA with respect to their human counterpart. As reviewed 
by Balan et  al. (165), no data indicate secretion of LL-37 by 
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muBMSCs, but the preconditioning with E. coli significantly 
increases the production of the antimicrobial protein Lcn2 
(26). Furthermore, in contrast to BMSCs of human origin, 
muBMSCs fail to express IDO even after stimulation with 
inflammatory cytokines such as IFNγ, tumor necrosis alpha, 
and IL-1β, and they consequently do not inhibit bacterial 
growth (16). However, it has been reported that unstimulated 
muBMSCs directly exhibit phagocytic activity for E. coli or 
S. aureus in a cell dose-dependent manner (25), although 
further studies are required to confirm these claims.
More recently, menstrual fluid-derived MSCs (MenSCs) 
have emerged as an attractive alternative for cell therapy since 
they are isolated in a non-invasive manner with the possibility 
of periodical collections from the same donor, ensuring high 
amounts of cells at low culture passages and from the same 
genetic background (2, 6). Our group has recently shown that 
MenSCs have an important antimicrobial effect mediated by 
hepcidin, both directly and through the peptide present in their 
conditioned medium. Polybacterial stimulation significantly 
increased the expression of hepcidin in MenSCs, whereas other 
antimicrobial peptides such as LL-37 and hBD-1-2-3 remained 
below the limit of detection (20). Interestingly, the downregula-
tion of hepcidin through hypoxic condition resulted in the loss 
of the antimicrobial property of MenSCs, indicating a hepcidin-
dependent mechanism (20). Therefore, culture condition need to 
be carefully considered when expanding MenSCs as any modifi-
cation in the oxygen levels can affect their biological activities and 
consequently, their antimicrobial potential. In that perspective, 
the effect of hypoxia on MenSCs functions could be considered 
as a negative regulator of their antimicrobial activity (20) but is 
contrasted with a positive effect on their angiogenic property (2). 
Nevertheless, the extend of the effect of this type of conditioning 
is largely dependent on the source of MSCs, as an example, it has 
been observed that the immunosuppressive capacity of AT-MSCs 
remains unchanged under hypoxic conditions (166).
Sung et al. (24) described that the growth of E. coli in vitro 
was significantly inhibited by UC-MSCs or their conditioned 
medium after bacterial exposure. In microarray analysis per-
formed to detect gene expression changes in MSCs responsible 
for their antibacterial action, a significant upregulation of toll-
like receptor (TLR)-2 and TLR-4, and hBD-2 were identified in 
UC-MSCs after E. coli exposure, suggesting that the antimicrobial 
effects of MSCs might be mediated by the secretion of hBD-2 
via TLR signaling pathway. However, the increased hBD-2 level 
and the in vitro antibacterial effects of MSCs were abolished by 
specific antagonist or by silencing of the TLR-4, but not TLR-2. 
The effect was restored by hBD-2 supplementation, indicating 
that hBD-2 secreted by MSCs only via TLR-4 mediates the 
antibacterial effects. In this study, the gene expression profiles of 
other antimicrobial proteins, such as LL-37 (19, 23) or Lcn2 (26), 
were not significantly upregulated.
AT-MSCs or their conditioned medium have also shown an 
antimicrobial effect. Sutton et al. (23) report that the conditioned 
medium of AT-MSCs decreased the P. aeruginosa growth rate 
to levels comparable with the AB geneticin, a broad-spectrum 
aminoglycoside AB. Importantly, the combination of AT-MSCs 
with geneticin showed a potent antimicrobial effect against 
P. aeruginosa, revealing that this type of stromal cells have an 
AB-enhancing effect.
In Vivo Studies
The in vitro data demonstrating the antimicrobial effect of MSCs 
have also been supported by in vivo studies. MSCs from different 
sources or origins have the capability to reduce the burden of 
pathogens in different preclinical models, independently of the 
route of administration, doses, or time of injections, having been 
shown in blood, spleen, peritoneum, lung, and bronchoalveolar 
lavage (BAL) fluid (17–23, 25, 26, 30). In Table 5, we summarize 
the current in vivo data regarding antimicrobial effector function 
of MSCs mediated by AMPs.
In an immunocompetent model of pneumonia by E. coli, 
the treatment with 1 ×  106 BMSCs after 4  h of E. coli instilla-
tion induced a sharp reduction in total bacterial counts in lung 
homogenates (LH) and BAL fluid compared with vehicle (19). 
Total BAL cell counts and absolute neutrophil counts were also 
lower in the BMSCs-treated group, suggesting that bacterial 
clearance in the BAL of BMSC-treated mice did not primarily 
depend on the recruitment of immune cells. In fact, the adminis-
tration of BMSCs together with neutralizing anti-LL-37 antibody 
resulted in a 10-fold increase in bacterial number both in LH and 
BAL, revealing that LL-37 effect is needed for the antimicrobial 
activity of BMSCs in vivo (19). These results are in line with Sung’s 
work (24), where in the same model, the treatment with 1 × 105 
UC-MSCs administered intratracheally after 3 h of E. coli instil-
lation provoke a downregulation of the inflammatory response 
and enhanced bacterial clearance, increased hBD-2 secretion in 
BAL fluid and the resultant protection against E. coli-induced 
pneumonia. Since hBD-2 secreted by MSCs are via the TLR-4 
pathway, the antibacterial effects of UC-MSCs were abolished 
with TLR-4 siRNA transfection of UC-MSCs. Likewise, the 
detection of hBD-2 in BAL fluid, suggests that hBD-2 secreted 
by transplanted UC-MSCs plays a pivotal role in mediating the 
in vivo antibacterial effects of UC-MSCs (24). Similarly, another 
study with similar preclinical model setting described that the 
concentration of the antimicrobial molecule Lcn2 in BAL fluid is 
increased after the transplantation of muBMSCs; and the block-
ing of Lcn2 by a monoclonal antibody results in the elimination 
of the antibacterial effect of MSCs treatment in vivo (26).
In immunocompetent mice with a polymicrobial sepsis 
induced by cecal ligation and puncture (CLP), the administration 
of MSCs, either of human or murine origin, induced a reduction 
of the burden of pathogens and also a significant improvement 
in the survival rate (17, 20, 22, 25, 30). Our group has recently 
shown that the administration of 7.5 ×  105 MenSCs 3  h after 
CLP-induced sepsis is able to reduce the animal mortality 
regulating different aspects of the septic process, such as the 
organ dysfunction, modulation of the inflammatory response 
without severe immunosuppression, and promotion of bacterial 
clearance in blood, in a similar degree to the present standard of 
treatment with AB therapy (20). Notably, the synergism between 
MenSCs + AB resulted in the highest improvement of survival 
(20). Although the in  vivo role of hepcidin was not evaluated, 
the in vitro data suggest a potential antibacterial effect of hepci-
din in the resolution of the bacteremia. In line with these data, 
TABLe 5 | Summary of studies reporting direct antibacterial effect of MSCs by AMPs.
Model MSCs type/
route
Pre-
conditioning
In vitro findings In vivo findings Reference
Mouse model of 
Escherichia coli pneumonia 
(C57BL/6 mice)
BMSCs/it E. coli ↑ LL-37 ↓ Bacterial growth in lungs and in BAL fluid (19)
↑ Inhibition of bacterial 
growth (E. coli, Pseudomonas 
aeruginosa, S. aureus)
Mouse model of CLP-
induced sepsis (C57BL/6j 
mice) 
MenSCs/ip Unstimulated 
and stimulated 
with bacterial 
mix
↑ Hepcidin
↑ Inhibition of bacterial growth
↑ Survival (20)
↓ Lung injury
↑ Bacterial clearance in the peritoneal fluids and blood
Modulation of inflammatory response
Mouse model of cystic 
fibrosis (CFTRtmlKth mice)
BMSCs 
AT-MSCs/
retro-orbital 
sinus
Unstimulated 
and stimulated 
with IFNγ, IL-1β, 
or IL-12
↑ LL-37 ↓ Bacterial growth in BAL fluid (23)
↑ Inhibition of bacterial growth 
(P. aeruginosa; S. aureus; S. 
pneumoniae)
Mouse model of E. coli 
pneumonia (ICR mice)
UC-MSCs/it E. coli ↑ hBD-2
↑ Inhibition of bacterial growth 
(E. coli)
↓ Alveolar congestion, hemorrhage, neutrophil 
infiltration, and wall thickening
(24)
↓ Bacterial growth, protein concentrations and cytokine 
levels (IL-1α, IL-1β, IL-6, and TNFα) in BAL fluid
↑ hBD-2 in BAL fluid
Mouse model of Gram-
negative pneumonia 
(C57BL/6 mice)
muBMSCs/it LPS and TNFα ↑ Lipocalin-2
↑ Phagocytic activity
↑ Survival (26)
↓ Lung injury
↑ Bacterial clearance from the alveolar space
↓ MIP-2, TNFα, and MPO in BAL fluid
↑ Lipocalin-2 in BAL fluid
MSCs, mesenchymal stem cells; BMSCs, bone marrow MSCs; muBMSCs, murine BMSCs; MenSCs, menstrual MSCs; AT-MSCs, adipose tissue MSCs; UC-MSCs, umbilical cord 
MSCs; it, intratracheal; ip, intraperitoneal; CLP, cecal ligation and puncture; BAL, bronchoalveolar lavage; CM, conditioned media; IFNγ, interferon gamma; IL, interleukin; hBD-2, 
human β-defensin-2; TNFα, tumor necrosis factor alpha; LPS, lipopolysaccharide; MIP-2, macrophage inflammatory protein 2; MPO, myeloperoxidase.
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Gonzalez-Rey et al. (17) described that AT-MSCs-treated septic 
mice have lower peritoneal bacterial counts than untreated mice, 
suggesting that AT-MSCs could promote bactericidal activities 
by themselves or on other cell types. Concordantly, Mei et  al. 
(25) reported that 2.5 ×  105 muBMSCs administered 6  h after 
CLP-induced sepsis results in a higher bacterial clearance in part 
due to enhanced phagocytotic activity of the host immune cells.
Cystic fibrosis is a genetic disease in which the battle between 
pulmonary infection and inflammation becomes the major cause 
of morbidity and mortality. In a mouse model of cystic fibrosis 
infected with P. aeruginosa and S. aureus, the administration of 
1 × 106 BMSCs or its conditioned medium results in a reduction 
of the CFU of these two pathogens in BAL fluid. Although the role 
of the peptide LL-37 was not evaluated in vivo, the in vitro data 
showing the constitutive or stimulated expression of LL-37 sug-
gest a potential role for this peptide in the reduction of bacterial 
growth in vivo (23).
ARe ANTiMiCROBiAL eXTRACeLLULAR 
veSiCLeS, THe NeXT BiG THiNG FOR 
iNFeCTiOUS DiSeASeS?
Extracellular vesicles released by cells act as key agents in intercel-
lular communications through transfer of information via their 
cargo, which includes proteins, DNAs, and RNAs (167). The active 
biological role of cell-derived vesicles in pathological conditions 
such as ischemic heart disease, kidney injury, and wound healing 
have been shown to share many similar therapeutical features of 
their parent cells (15). While EVs [mainly microvesicles (MVs) 
and exosomes] are gaining momentum in the regenerative 
medicine field as a putative surrogate to cell-based therapeutics 
(168) their application in infectious diseases still requires further 
exploration.
Recently, AMPs were identified in different EVs isolated from 
body fluids and selective enrichment was related to specific 
diseases. Hiemstra et  al. (169) reported that exosomes isolated 
from normal human urine contain innate immune proteins that 
include antimicrobial agents. The analyzed list included lysozyme 
C, dermcidin, mucin-1, calprotectin, and myeloperoxidase, all 
known for their bactericidal effect. The antimicrobial activity of 
urinary exosomes was determined through their in vitro incuba-
tion with E. coli, reporting that these exosomes were able to induce 
bacterial lysis and inhibit their growth in vitro, observations that 
reinforce the claim that exosomes are innate immune effectors 
that contribute to host defense. Similarly, exosomes isolated from 
nasal lavage fluids were shown to contain proteins with immune-
related functions relevant in the first line of defense against 
pathogens and allergens. Thus, the analysis of the alterations in 
the exosomes proteome as a result of a chronic airway inflam-
mation revealed that serum-associated proteins and mucins were 
more abundant in exosomes from subjects with airway diseases 
compared to healthy subjects while proteins with antimicrobial 
functions and barrier-related proteins had decreased expression 
(170). Also, biliary and intestinal epithelium luminal release 
exosomes that are increased following infection by a protozoan 
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parasite, carrying AMPs of epithelial cell origin, including LL-37 
and hBD-2. Activation of TLR-4 signaling enhances exosome-
mediated shuttle of epithelial AMPs from the gastrointestinal 
epithelium, revealing a new arm of mucosal immunity relevant 
to antimicrobial defense (171).
As discussed in this review, MSCs exert strong antimicrobial 
effects through paracrine release of several antimicrobial fac-
tors. However, future experimental designs are still required to 
demonstrate whether some of these effects are mediated by EVs.
Potential Antibacterial Activity of evs 
Released from MSCs
Recent studies have ignited significant interest on EVs released 
by MSCs accounting, at least in part, on their paracrine effect 
resulting in a horizontal transfer of the nucleic acids and proteins 
between the injured cells and MSCs. This cell-to-cell interaction 
is doubt to be bi-directional, resulting in reprogramming of their 
secretome to respond to specific need of the tissue by transferring 
to the injured cells, factors restraining injury, and leading to tis-
sue regeneration. MSCs-derived EVs have been implicated in the 
tissue restoring effects of MSCs including, anti-apoptotic (172), 
wound healing (173), and anti-tumoral activities (168).
In the last few years, the beneficial role of MSCs-derived EVs 
has been described in several preclinical models of inflammatory/
infectious diseases. Zhu et al. (174) reported that MVs released by 
BMSCs were therapeutically effective following E. coli endotoxin-
induced acute lung injury (ALI) in mice, in part through the 
transfer of keratinocyte growth factor (KGF) mRNA from the 
MVs to the injured alveolar epithelium and lung endothelium. 
In line, Monsel et  al. showed that the administration of MVs 
secreted by BMSCs improved survival, and decreased the influx 
of inflammatory cells and bacteria in a bacterial pneumonia 
mouse model. The antimicrobial effect of BMSCs-derived MVs 
was in part through enhancement of monocyte phagocytosis of 
bacteria, which could be further increased by pre-stimulation of 
BMSCs with a TLR-3 agonist before the release of MVs (175). 
However, it remains to be explored whether MVs released from 
MSCs conserve the cell antimicrobial effect through their AMPs 
content. Future experimental designs are required to explicitly 
address their antimicrobial relevance in the previously evaluated 
infectious disease models. Furthermore, the exposure of MSCs to 
conditions that are known to upregulate the expression of AMPs 
such as cytokines (IFNγ, TNFα, IL-22, etc.), growth factors, and 
UV exposure should be considered (Figure 1). Additionally, the 
effect of the conditioning on increasing the MVs cargo content 
with AMPs will also need to be evaluated. Nevertheless, in other 
applications, it has been demonstrated that MVs can transport 
drugs to target sites and maintain a higher drug concentration than 
conventional dosage forms. Tang et al. engineered drug-packaging 
MVs by incubating cells with chemotherapeutic agents. These 
hybrid MVs were used to effectively kill tumor cells in murine 
tumor models without typical side effects (176). More recently, 
another group assessed the feasibility of an exosome-based drug 
by loading a chemotherapeutic agent through sonication to treat 
multidrug-resistant cancer. Interestingly they observed a 50-fold 
increase in the cytotoxicity in drug-resistant cancer cells (177). 
This is a relevant outcome as it limits the side effect related to 
the conventional administration of chemotherapies and advance 
a novel and sustained drug release method.
Similar drug loading strategy could be evaluated based on 
AMPs packaging in EVs. The rationale for EVs loaded with AMPs 
is the possibility to enhance their therapeutic potential through 
increasing their concentrations at the site of infection and/or by 
reducing the toxicity of ABs.
TReNDS, FUTURe PeRSPeCTiveS, 
AND CHALLeNGeS
Aside from the direct administration of synthetic or natural 
AMPs through drug or MSCs infusion, there are several ongoing 
clinical studies aimed at modulating the expression of AMPs by 
the endogenous cells in the body, through dietary nutrients and 
vitamins, to boost the innate immune response (178). Indeed, 
Vitamin D3 has been shown to directly regulate expression of 
the human antimicrobial peptides LL-37 and hBD-2 (179, 180). 
However, a recent pilot study in mechanically ventilated ICU 
patients showed that high dose of vitamin D3 was associated 
with decreased hospital length of stay, but no statically sig-
nificant change in plasma LL-37 concentrations or other clinical 
outcomes (181). While the stimulatory effect of Vitamin D has 
been described for the osteogenic potential of MSCs (182), future 
experiments are required to address their effect on the expression 
of AMPs both in vitro and in vivo. This could represent an alter-
native approach by stimulating the endogenous MSCs to secrete 
higher amount of AMPs.
The urgent need for new strategies has become evident due 
to increasing drug resistance. Discovering new classes of anti-
microbials or AMPs is a very promising approach but it might 
not be the only strategy required for defeating this threat. In fact, 
enhancing AMPs delivery, bioavailability, liberation, absorption, 
half-life while reducing their clearance and side effect can also 
denote an additional booster for overcoming infections.
Mesenchymal stem cells present desirable features to improve 
the pharmacokinetics of natural AMPs, their stem cell-related 
“arsenal” includes
 (a) Sensors, able to detect and react following an infection 
signal, triggering an immediate mobilization and a mi-
gration shift toward the site of infection.
 (b) Bioactive pumps, able to control on-demand the conti-
nuous release of AMPs in the site of infection.
 (c) Watchtowers, able to release specific combinations of 
AMPs depending on the stimulus.
Standpoint efforts focusing on enhancing these MSC features 
through genetic modifications or preconditioning, in addition 
to deciphering the multi-target drug status of AMPs (indirect 
and direct targets), should synergistically lead to key advances 
against infections caused by drug-resistant strains. Nonetheless, 
despite these advantageous features, there are still some chal-
lenges hindering their applications, such as high production 
costs (when compared to generic ABs), in addition to storage 
FiGURe 1 | A schematic representation depicting the mesenchymal stem cells (MSCs) secretion of different AMPs, following different hypothetical 
preconditioning to enhance their expression, secretion, or encapsulation in extracellular vesicles (evs), based on the known regulation of the 
expression of each AMPs. Also, the bacterial or inflammatory stimulation is shown. LL-37 secretion was shown to possess a bactericide effect on both S. aureus 
and Escherichia coli, while the β-defensin-2 effect was demonstrated in E. coli alone. MSCs isolated from menstrual fluids were able to secrete hepcidin that was 
shown to inhibit the growth of a polybacterial mix isolated from mice microflora. Extracellular vesicles can also be secreted by MSCs and possibly contain active 
agents with potential antimicrobial effect. This will require further investigation in the future. Abbreviations: IFNγ, interferon gamma; TNFα, tumor necrosis factor 
alpha; BMP6, bone morphogenetic protein 6; AMPs, antimicrobial peptides.
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problems including “off-the-shelf ” and ready-to-use dosage 
shortage.
New perspective tools based on unmodified or drug-loaded 
EVs are looming in the horizon. These thriving alternatives need 
further development and investigation to achieve maximum kill-
ing efficiency, less side effects, and null drug-resistant infections. 
Indeed, the prospect of using concentrations below the minimum 
inhibitory concentration might contribute to limit the emergence 
of AB resistance due to drug-resistant strains. However, one 
should keep in mind that the mechanism and effect of EVs on 
extracellular bacterial clearance might be different in comparison 
to intracellular bacteria, and this will require additional consid-
eration in the experimental design. The actual trend in the field 
positions MSCs-derived EVs (with or without drug loading), as 
important candidates to be exploited as novel “ready-to-inject” 
biologics, in infectious diseases as an alternative to stem cell-
based therapy.
CONCLUSiON
Mesenchymal stem cells exert strong antimicrobial effects through 
indirect and direct mechanisms, partially through the secretion 
of AMPs. The bacterial clearance observed in preclinical models 
including sepsis, ARDS, and cystic fibrosis infection, can be fur-
ther enhanced following specific preconditioning protocols. We 
propose possible strategies to increase the expression and secre-
tion of these AMPs to enhance their antimicrobial effect. These 
conditions include the exposure of MSCs to cytokines, growth 
factors, and UVB light. Furthermore, studies evaluating the pres-
ence of AMPs in the cargo of EVs will represent an opportunity 
to develop new drug delivery tools. The potential antimicrobial 
activity of MSCs-derived EVs can also be heightened through 
cell conditioning and/or drug loading. Finally, the enhanced 
antimicrobial potential of MSCs through AMPs secretion or 
encapsulation present an important potential to be exploited as 
an improved therapeutic approach for infectious diseases.
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